Neo-Epitopes Identification for T cell Response Studies in Cancer
Immuno-oncology encompasses treatments that stimulate the immune system to combat cancer. One area that is gaining a lot of attention within immuno-oncology and where neo-epitope mapping is of importance is personalised cancer vaccines. Here, information about an individual’s own tumour is exploited to develop a vaccine that can boost the patient’s immune response towards their specific cancer.
At Immunitrack we seek to help in mapping which epitopes are most likely to stimulate a T cell response for the purposes of understanding better the dynamics from mutation, presentation to T cell stimulation. Next generation sequencing of tumour biopsies allows personalised identification of cancer-specific mutations and facilitates predictions about neo-epitopes i.e. cancer-specific epitopes that can be used to stimulate an individual’s immune system to attack their specific cancer type or study patient neo-epitope specific T cell responses
Immunitrack’s NeoScreen® platform technology supports early stage study of neo-epitopes by facilitating rapid high-throughput screening of major histocompatibility complex class I and II (MHC I & II) interactions with candidate neo-epitopes to identify epitopes as illustrated in Figure 1.